Anidulafungin;Anidulafungina

Revista Espanola de Quimioterapia

Volumn 21, Issue 2, 2008, Pages 99-114

  Gobernado Serrano, Miguel ^a   Canton E ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Anidulafungin; Aspergillus spp.; Candida spp.

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CILOFUNGIN; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; PEPTIDASE; PROTEINASE; TACROLIMUS; VORICONAZOLE;

AGE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; ASPERGILLUS; BODY WEIGHT; CANDIDA; CANDIDEMIA; CANDIDIASIS; CELL COMPOSITION; CELL WALL; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG DEGRADATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FACE ERYTHEMA; FEVER; FUNGAL CELL; FUNGICIDAL ACTIVITY; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOTENSION; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; MAMMAL CELL; MOULD; MYCOSIS; NAUSEA; NEUTROPENIA; NITROGEN URINE LEVEL; NONHUMAN; NONVERBAL COMMUNICATION; PHLEBITIS; PROTEIN SYNTHESIS; PRURITUS; RASH; REVIEW; SEX DIFFERENCE; SIDE EFFECT; URTICARIA; VOMITING; YEAST;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; DISEASE MODELS, ANIMAL; ECHINOCANDINS; HUMANS; MYCOSES;

EID: 47649126511     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-803.
2. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-7.
3. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 2001;7(Suppl. 2):1-7.
4. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66.
5. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006;20:485-506.
6. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43(Suppl.):S3-14.
7. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63.
8. Samaranayake LP. Oral mycoses in HIV infection. Oral Surg Oral Med Oral Patho 1992;73:171-80.
9. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27:781-8.
10. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17.
11. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319-24.
12. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9.
13. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006;34:857-63.
14. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, for the National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35:627-30.
15. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.
16. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al., for the NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634-43.
17. Ostosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2000 bloodstream Candida Isolates in the United States. Antimicrob. Agents Chemother 2003;47:3149-54.
18. Hajjeh RA, Sofair AN, Harrison LH, Marshall Lyon G, Arthington-Skaggs BA, Mirza SA, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519-27.
19. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-407.
20. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DRJ, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93.
21. Fromtling RA. Human mycoses and advances in antifungal therapy. Drug News Perspect 2001;14:281-92.
22. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003;20:121-36.
23. Serrano MC, Valverde-Conde A, Chávez M , Bernal S, Claro R, Pemán J, et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 2003;45:131-5.
24. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50: 2009-15.
25. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 5425-7.
26. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51.
27. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006;42:1171-8.
28. von Benz F, Knusel F, Nuesch J. Echinocandin B, ein neuartiges polipeptide-antibiotikum aus Aspergillus nidulans var. echinatus: Isolierung und Bausteine. Helvetica Chimica Acta 1974;57:2459-77.
29. Nyfeler R, Keller S W. Metabolites of microorganisms, 143: echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var echinulatus-isolation and structural components. Helv Chim Acta 1974;57:2459-77.
30. Schwartz RE, Giacobbe RA, Boand JA, Monaghan RL. L-671,329, a new antifungal agent. I. Fermentation and isolation. J. Antibiot 1989;42:163-7.
31. Masurekar PS, Fountoulakis JM, Hallada TC, Sosa MS, Kaplan L. Pneumocandins from Zalerion arboricola, II: modification of product spectrum by mutation and medium manipulation. J Antibiot (Tokyo) 1992;45:1867-74.
32. Iwamoto T, Fujie A, Nitta K, Hashimoto S, Okuhara M, Kohsaka M. WF11899A, B and C, novel antifungal lipopeptides, I: taxonomy, fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo) 1994;47:1084-91.
33. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007;27:369-88.
34. Cassone A, Mason RE, Kerridge D. Lysis of growing yeast-form cells of Candida albicans by echinocandin; a cytological study. Sabouraudia 1981;19:97-110.
35. Cabib E, Kang MS. Fungal 1,3-b-glucan synthase. Methods Enzymol 1987;138:637-42.
36. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993;6:1-21.
37. Eng WK, Faucette L, McLaughlin MM, Cafferkey R, Koltin Y, Morris RA, et al. The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth. Gene 1994;151:61-71.
38. Denning DW. Echinocandins and pneumocandins A new antifungal class with a novel mode of action. J Antimicrob Chemother 1997;40:611-4.
39. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994;48:471-97.
40. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994;38:1480-9.
41. Kelly R, Register E, Hsu MJ, Kurtz M, Nielsen J. Isolation of a gene involved in 1,3-beta-glucan synthesis in Aspergillus nidulans and purification of the corresponding protein. J of Bacteriol 1996;178:4381-91.
42. Douglas C. Fungal beta (1,3)-D-glucan synthesis. Med Mycol 2001;39(Suppl. 1):55-66.
43. Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999;33:75-80.
44. United States Pharmacopeia. Anidulafungin. Drug Standards Pharmacopeial Forum 2000; 26. Available at: http:// http://www.usp.org/USPNF/pf/2602/f01.html. Accessed July 14, 2006.
45. Ernst ME, Klepser ME, Wolfe EJ, Pfaller MA. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida spp. Diagn Microbiol Infect Dis 1996;26: 125-31.
46. Uzun O, Kocagoz S, Cetinkaya Y, Arikan S, Unal S. In vitro activity of a new echinocandin, LY-303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother 1997;41:1156-7.
47. Pfaller MA, Messer SA, Coffman S. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY-303366, and other antifungal agents. Antimicrob Agents Chemother 1997;41:763-6.
48. Zhanel GG, Karlowsky JA, Harding GAJ, Balko TV, Zelenitsky SA, Friesen M, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis and Aspergillus species. Antimicrob Agents Chemother 1997;41:863-5.
49. Zhanel GG, Karlowsky JA, Zelenitsky SA, Turik MA, Hoban DJ. Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY-303366 and other antifungal agents. Antimicrob Agents Chemother 1998;42:2446-8.
50. Cuenca-Estrella M, Mellado E, Díaz-Guerra TM, Monzón A, Rodríguez-Tudela JL. Susceptibility of fluconazole resistant clinical isolates of Candida spp. to echinocandin LY-303366, itraconazole and amphotericin B. J Antimicrob Chemother 2000;46:475-7.
51. Moore CB, Oakley KL, Denning DW. In vitro activity of a new echinocandin, LY-303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect 2001;7:11-6.
52. Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother 2004;54:2051-6.
53. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY-303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6.
54. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008;46:150-6.
55. Cota J, Carden M, Graybill JR, Najvar LK, Burgess DS, Wiederhold NP. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 2006;50:3926-8.
56. Wiederhold NP, Najvar LK, Bocanegra R, Molina D, Olivo M, Graybill JR. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007;51:1616-20.
57. Petraitis V, Petraitiene R, Groll AH, Sein T, Schaufele RL, Lyman CA, et al. Dosage dependent antifungal efficacy of V-echinocandin (LY-303366) against experimental fluconazoleresistant oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2001;45: 471-9.
58. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother 2004;48:1912-5.
59. Moudgal V, Little T, Boikov D. Multiechinocandin and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005;49:767-9.
60. Karlowsky JA, Harding GA, Zelenitsky SA, Hoban DJ, Kabani A, Balko TV, et al. In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and resistant Candida species. Antimicrob Agents Chemother 1997;41:2576-8.
61. Cantón E, Pemán J, Valentín A, Bosch M, Espinel-Ingroff A. Pharmacodynamics of anidulafungin against six Candida species. J Chemother 2007;19:42.
62. th Congress of Chemotherapy. Munich, 2007. Abstract 1955.
63. Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents 2006;27:174-77.
64. Ernst EJ, Klepser MF, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 200;44:1108-11.
65. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother 2007;51:2257-9.
66. Jacobsen MD, Whyte JA, Odd FC. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. Antimicrob Agents Chemother 2007;51:1882-4.
67. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi. Diagn Microbiol Infect Dis 1998;30:251-5.
68. Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L. In vitro synergy testing of anidulafungin con itraconazole voriconazole and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005;49:3572-4.
69. Brummer E, Chauhan SD, Stevens DA. Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus. J Antimicrob Chemother 1999;43:491-6.
70. Bartlett MS, Current WL, Goheen MP, Boylan CJ, Lee CH, Shaw MM, et al. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 1996;40: 1811-6.
71. Potera C. Forging a link between biofilms and disease. Science 1999;283:1837-9.
72. Katragkou A, Chatzimoschou A, Simitsopoulou M, Dalakiouridou M, Diza-Mataftsi E, Tsantali C, et al. Candida albicans y Candida dubliniensis respond different to echinocandin antifungal agents in vitro. Antimicrob Agents Chemother 2008;52:357-60.
73. Valentin A, Cantón E, Pemán J, Quindos G. Actividad in vitro de la amfotericina B y la anidulafungina sobre biopelículas de Candida albicans y Candida tropicalis. Rev Iberoam Micol 2007;24:272-7.
74. Cantón E, Valentín A, Pemán J, Bosch M, Gobernado M. In vitro activity of anidulafungin and micafungin against Candida albicans and Candida tropicalis biofilms. J Chemotherapy 2007(Suppl. 3);19:41.
75. Pemán J, Cantón E, Valentín A. Actividad de Ila anidulafungina sobre biopelículas fúngicas. Rev Iberoam Micol 2008;25:122-6.
76. Jones RN, Kirby JT, Messer SA, Sheehan DJ. Development of anidulafungin for disk diffusion susceptibility testing against Candida spp. Diagn Microb Infect Dis 2007;58:371-4.
77. Cantón E, Pemán J, Valentín A, Bosch, Gobernado M. Evaluación de dos métodos para determinar la actividad de anidulafungina. Rev Iberoam Micol 2006;23:S20.
78. Ostrosky-Zeichner L, Pfaller M, Diekma D. A Proposal for an antifungal susceptibility testing (AST) breakpoints for micafungin (MFG) and Candida: integration of AST surveys and correlation with clinical outcomes. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 17-20, 2007 Chicago, IL. Abstract M-2020.
79. Espinel-Ingroff A, Fothergill A, Ghannoum M, Manavathu E, Ostrosky-Zeichner L, Pfaller MA, et al. Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. J Clin Microbiol 2007;45:2180-2.
80. Pfizer Inc. Eraxis (anidulafungin) package insert. New York, 2006.
81. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004;48:2021-4.
82. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39: 770-5.
83. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356: 2472-82.
84. Cohen-Wolkowiez M, Benjamin DK, Steinbach WJ, Smith PB. Anidulafungin: a new echinocandin for the treatment of fungal infections. Drugs Today 2006;42:533-44.
85. Kim R, Khachikian D, Reboli AC. Comparative evaluation of properties and clincal efficay of the echinocandins. Expert Opin Pharmacother 2007;8:1479-92.
86. Wagner C, Graninger W, Presterl E, Joukhada C. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006;78:161-77.
87. Theuretsbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004;23:805-12.
88. Thye D, Shepard B, White RJ. Anidulafungin: A phase 1 study to identify the maximum tolerated dose in healthy volunteers. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, Ill. December 16-19, 2001. Abstract A-36.
89. Stogniew M, Pu F, Henkel T, Dowell J. Anidulafungin biotransformation in humans is by degradation not metabolism. Presented at: The 13th European Congress of Clinical Microbiology and Infectious Diseases, May 10-13, 2003, Glasgow, UK. Abstract 1223.
90. Kelley K, Chapman S, Cleary J. Digestion of echinocandins. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sep. 27-30, 2006, San Francisco, CA. Abstract M-366.
91. Gupta NK, Woodley CL, Fried R. Effect of metronidazole on liver alcohol dehydrogenase. Biochem Pharmacol 1970;19: 2805-8.
92. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44:590-8.
93. Dowell J, Stogniew M, Krause D. Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. J Clin Pharmacol 2007;47:461-70.
94. Thye D, Marbury T, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: pharmacokinetics in subjects with severe hepatic impairment. Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, CA, USA. Abstract 1392.
95. Thye D, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: pharmacokinetics in subjects receiving hemodialysis. Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, CA, USA. Abstract 1390.
96. Benjamin DK DK Jr, Driscoll T, Seibel NL, Gonzalez CE, Roden MM, Kilaru R, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006;50:632-8.
97. Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005;45:1373-82.
98. Schranz J, Dowell J, Krause D, Henkel T. Anidulafungin and cyclosporin: safe coadministration without dosing adjustment. Presented at: The 15th Congress of the International Society for Human and Animal Mycology, May 25-29, 2003, TX, USA.
99. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporin. J Clin Pharmacol 2005;45:227-33.
100. Dowell JA, Stogniew M, Krause D, Henkel T. Anidulafungin pharmacokinetic/pharmacodynamic correlation: treatment of esophageal candidiasis. Presented at: The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, 2003, IL, USA. Abstract 1578.
101. Dowell J, Schranz J, Stogniew M. Assessment of the pharmacokinetics of anidulafungin in patients with invasive aspergillosis receiving concomitant liposomal amphotericin. Presented at: The 14th European Congress of Clinical Microbiology and Infectious Diseases, May 1-4, 2004, Prague, Czech Republic. Abstract 1036.
102. Park S, Kelly R, Nielsen Kahn J, Robles J, Hsu MJ, Register E, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005;49:3264-73.
103. Brielmaier BD, Casabar E, Kurtzeborn CM, McKinnon PS, Ritchie DJ. Early clinical experience with anidulafungin at a large tertiary care Medical Center. Pharmacother 2008;28:64-73.
104. Hernández S, López-Ribot JL, Najvar LK, McCarthy DI, Bocane-gra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testings of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004;48:1382-3.
105. Baixench MT, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 2007;59:1076-83.
106. Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006;57:705-8.
107. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006;50:2522-4.
108. Kahn JN, García-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007;51:1876-8.
109. Rocha EM, García-Effron G, Park S, Perlin DS. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2007;51:4174-6.
110. Rogers TR, Johnson EM, Munro C. Echinocandin drug resistance. J Invasive Fungal Infect 2007;1:99-105.
111. Petraitiene R, Petraitis V, Groll AH, Calendario M, Sein T, Bell A, et al. Antifungal activity of LY-303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 1999; 43:2148-55.
112. Groll AH., Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY-303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001;45:2845-55.
113. Gumbo T, Drusano GL, Liu W, Ma L, Deziel MR, Drusano MF, Louie A, et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006;50:3695-700.
114. Andes D, Diekema DJ, Pffaler MA, Prince RA, Marchillo K, Ashbeck J, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008;52: 539-50.
115. Petraitiene R, Petraitis V, Groll AH, Sein T, Schaufele RL, Francesconi A, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY-303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998;2:2898-905.
116. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000;44:3381-8.
117. Petraitis V, Petraitiene R, Hope W, Kelaher AM, Hughes JE, Cotton MO, et al. Combination therapy of voriconazole and anidulafungin improves outcome of experimental pulmonary aspergillosis. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2006 (abstract M-882).
118. Vázquez J, Schranz JA, Krause D, Goldstein BP, Reboli A, Hernández J, et al. Efficacy from a Phase 2/3 study of anidulafungin (ANID) in patients (pts) with azole-refractory mucosal candidiasis (ARMC). Presented at: The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC, USA. Abstract 1038 (2004).
119. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113: 294-9.
120. Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother 2005;49:4795-7.
121. Vázquez JA, for the Anidulafungin Invasive Candidiasis Study Group. A Phase 2, randomized, doser ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004;48:2021-4.
122. Arévalo MP, Carrillo-Muñoz AJ, Salgado J, Cárdenes D, Brió S, Quindós G, et al. Antifungal activity of the echinocandin anidulafugin (VER002-6, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob Chemother 2003; 5:163-6.
123. Ghannoum M, D'Angelo M. Anidulafungin: A potent antifungal that targets Candida and Aspergillus. Infect Dis Clin Pract 2005;13:165-78.